Citius Pharmaceuticals

Company snapshot

Citius Pharmaceuticals is a pharma organization headquartered in CRANFORD, NJ, USA. It trades on NYSE under ticker CTXR. NovaPharmaNews links 0 clinical program(s), 1 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• 1 approved product(s) across US/EU regulatory metadata.

Public regulatory, clinical, patent, and corporate records for Citius Pharmaceuticals. Not investment advice.

• approval Jun 2, 2026

  Citius Pharmaceuticals Stock Update: Cancer and Anti-Infective Pipeline Insights

• What is Citius Pharmaceuticals?

  Citius Pharmaceuticals is a pharma organization headquartered in CRANFORD, NJ, USA. It trades on NYSE under ticker CTXR. NovaPharmaNews links 0 clinical program(s), 1 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO source

• Is Citius Pharmaceuticals publicly traded?

  Yes. Citius Pharmaceuticals is listed with ticker CTXR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Citius Pharmaceuticals develop or market?

  We link 1 drug profile(s) where Citius Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/citius-pharmaceuticals#company-drugs.

• What are the latest developments for Citius Pharmaceuticals?

  Browse related news and pipeline sections on this page for coverage and ClinicalTrials.gov-linked program updates.

• What therapeutic areas does Citius Pharmaceuticals focus on?

  No specific therapeutic focus areas are currently identified for Citius Pharmaceuticals in our database.